Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | BLM | P54132 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 2/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | CASP7 | P55210 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4995016 | 0.68 | MEN1 (0.39) | ALDH1A1HPGDMAPTNPC1RAB9A | |
| SCHEMBL570221 | 0.67 | ALDH1A1 (0.46) | ALDH1A1KDM4EHSD17B10HPGDPOLB | |
| SCHEMBL1799678 | 0.67 | ALDH1A1 (0.63) | ALDH1A1KDM4EHSD17B10HPGDPOLB | |
| SCHEMBL577970 | 0.64 | KDM4E (0.56) | ALDH1A1KDM4EHSD17B10HPGDPOLB | |
| SCHEMBL8183045 | 0.64 | ALDH1A1 (0.43) | ALDH1A1KDM4EHSD17B10HPGDPOLB | |
| SCHEMBL1989146 | 0.63 | ALDH1A1 (0.42) | ALDH1A1KDM4EHSD17B10HPGDPOLB | |
| SCHEMBL13528571 | 0.61 | NPC1 (1.00) | ALDH1A1KDM4EHSD17B10HPGDPOLB | |
| SCHEMBL2114343 | 0.61 | MAPT (1.00) | ALDH1A1KDM4EHSD17B10HPGDPOLB | |
| SCHEMBL353240 | 0.61 | ALDH1A1 (0.45) | ALDH1A1KDM4EHSD17B10HPGDPOLB | |
| SCHEMBL1036366 | 0.61 | ALDH1A1 (0.45) | ALDH1A1KDM4EHSD17B10HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879604-B1 | PIF TETRAPEPTIDES | BIOINCEPT LLC (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3655010-A2 | PEPTIDES AND METHODS OF TRANSPLANTATION AND RESTORATIVE ORGAN FUNCTION | Bioincept LLC (US) | 2020-05-27 | — | — | EP | disclosed |
| WO-2019018447-A2 | PEPTIDES AND METHODS OF TRANSPLANTATION AND RESTORATIVE ORGAN FUNCTION | BIOINCEPT, LLC (US) | 2019-01-24 | — | — | WO | disclosed |
| EP-3377085-A1 | PEPTIDES AND METHODS OF TREATING ENDOMETRIOSIS USING THE SAME | Bioincept, LLC. (US) | 2018-09-26 | — | — | EP | disclosed |
| WO-2018156801-A2 | PEPTIDES AND METHODS OF TREATING DYSTROPHY-RELATED DISORDERS USING THE SAME | BIOINCEPT, LLC (US) | 2018-08-30 | — | — | WO | disclosed |
| EP-3341739-A1 | MUTANT PEPTIDES AND METHODS OF TREATING SUBJECTS USING THE SAME | BioIncept LLC (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-3341006-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODAMAGE | BioIncept LLC (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20170336406-A1 | PIF BINDING AS A MARKER FOR IMMUNE DYSREGULATION | BIOINCEPT, LLC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170319645-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RADIATION SYNDROME | BIOINCEPT, LLC (US) | 2017-11-09 | — | — | US | disclosed |
| EP-3215847-A1 | PIF BINDING AS A MARKER FOR IMMUNE DYSREGULATION | Bioincept LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2017079430-A1 | PEPTIDES AND METHODS OF TREATING ENDOMETRIOSIS USING THE SAME | BIOINCEPT, LLC (US) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017039751-A1 | MUTANT PEPTIDES AND METHODS OF TREATING SUBJECTS USING THE SAME | BIOINCEPT, LLC (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017040186-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODAMAGE | BIOINCEPT, LLC (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2016073513-A1 | PIF BINDING AS A MARKER FOR IMMUNE DYSREGULATION | BIOINCEPT, LLC (US) | 2016-05-12 | — | — | WO | disclosed |
| EP-1680442-A4 | PIF PEPTIDES BIOLOGIC ACTIVITIES, SITE OF ACTION, AND THE ANTIBODY TO DETECT PIF | BIOINCEPT LLC (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-1898942-A2 | ANTIPROLIFERATIVE PEPTIDES AND ANTIBODIES FOR THEIR DETECTION | Biospectrum, Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007129999-A2 | ANTIPROLIFERATIVE PEPTIDES AND ANTIBODIES FOR THEIR DETECTION | BIOSPECTRUM, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| EP-1680442-A2 | PIF PEPTIDES BIOLOGIC ACTIVITIES, SITE OF ACTION, AND THE ANTIBODY TO DETECT PIF | Bioincept, LLC. (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005040196-A2 | PIF PEPTIDES BIOLOGIC ACTIVITIES, SITE OF ACTION, AND THE ANTIBODY TO DETECT PIF | BIOINCEPT, LLC (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170336406-A1 | PIF BINDING AS A MARKER FOR IMMUNE DYSREGULATION | MIF, PGF, IRF2BP2 | ALDH1A1 2488/4885KDM4E 2968/4885HSD17B10 3518/4885 |
| US-20170319645-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RADIATION SYNDROME | FLT3, IGFBP1, CXCL12 | ALDH1A1 2375/4885KDM4E 4667/4885HSD17B10 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.